Hepatitis A Viral Safety of Plasma-Derived Factor VIII Concentrate Koate�-HP

2015 ◽  
pp. 80-82
Author(s):  
G. Mitra ◽  
M. Dobkin ◽  
M. Dumas ◽  
P. Ng ◽  
G. Roldan ◽  
...  
Keyword(s):  
Factor Viii ◽  
Hepatitis A ◽  
Viral Safety

Hepatitis A Viral Safety of Plasma-Derived Factor VIII Concentrate Koate®-HP

Vox Sanguinis ◽  
1994 ◽  
Vol 67 (1) ◽  
pp. 80-82
Author(s):  
G. Mitra ◽  
M. Dobkin ◽  
M. Dumas ◽  
P. Ng ◽  
G. Roldan ◽  
...  
Keyword(s):  
Factor Viii ◽  
Hepatitis A ◽  
Viral Safety

Hepatitis A Viral Safety of Plasma-Derived Factor VIII Concentrate Koate®-HP

Vox Sanguinis ◽  
1994 ◽  
Vol 67 ◽  
pp. 80-82 ◽  
Author(s):  
G. Mitra ◽  
M. Dobkin ◽  
M. Dumas ◽  
P. Ng ◽  
G. Roldan ◽  
...  
Keyword(s):  
Factor Viii ◽  
Hepatitis A ◽  
Viral Safety

“In vitro” and in Animal Model Studies on a Double Virus- Inactivated Factor VIII Concentrate

1995 ◽  
Vol 74 (03) ◽  
pp. 868-873 ◽  
Author(s):  
Silvana Arrighi ◽  
Roberta Rossi ◽  
Maria Giuseppina Borri ◽  
Vladimir Lesnikov ◽  
Marina Lesnikov ◽  
...  
Keyword(s):  
Heat Treatment ◽  
Animal Model ◽  
Factor Viii ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Virus Inactivation ◽  
Enveloped Viruses ◽  
Model Studies ◽  
Heat Treated

SummaryTo improve the safety of plasma derived factor VIII (FVIII) concentrate, we introduced a final super heat treatment (100° C for 30 min) as additional virus inactivation step applied to a lyophilized, highly purified FVIII concentrate (100 IU/mg of proteins) already virus inactivated using the solvent/detergent (SID) method during the manufacturing process.The efficiency of the super heat treatment was demonstrated in inactivating two non-lipid enveloped viruses (Hepatitis A virus and Poliovirus 1). The loss of FVIII procoagulant activity during the super heat treatment was of about 15%, estimated both by clotting and chromogenic assays. No substantial changes were observed in physical, biochemical and immunological characteristics of the heat treated FVIII concentrate in comparison with those of the FVIII before heat treatment.

Study of viral safety of Scottish National Blood Transfusion Service factor VIII/IX concentrate

1993 ◽  
Vol 3 (4) ◽  
pp. 295-298 ◽  
Author(s):  
B. Bennett ◽  
A. A. Dawson ◽  
B. S. Gibson ◽  
A. Hepplestone ◽  
G. D. O. Lowe ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Factor Viii ◽  
Service Factor ◽  
Viral Safety ◽  
Blood Transfusion Service

Detection of Hepatitis A Virus in a Factor VIII Preparation by Antigen Capture/PCR

Vox Sanguinis ◽  
1994 ◽  
Vol 67 (1) ◽  
pp. 57-61 ◽  
Author(s):  
Andrea Normann ◽  
Judith Graff ◽  
Bertram Flehmig
Keyword(s):  
Factor Viii ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Antigen Capture

scholarly journals Commercial factor VIII associated hepatitis, 1974–75, in the United Kingdom: a retrospective survey

1978 ◽  
Vol 80 (3) ◽  
pp. 327-336 ◽  
Author(s):  
J. Craske ◽  
P. Kirk ◽  
B. Cohen ◽  
Elise M. Vandervelde
Keyword(s):  
United Kingdom ◽  
Hepatitis B ◽  
Factor Viii ◽  
Incubation Period ◽  
Hepatitis A ◽  
Retrospective Survey ◽  
Factors Affecting ◽  
The United Kingdom ◽  
Surface Antibody

SummaryA retrospective survey of transfusion hepatitis associated with a brand of commercial Factor VIII was carried out in 24 Haemophilia Centres from January 1974 until December 1975. Of 371 patients who were transfused with this product, and were followed up, 78 cases of hepatitis affecting 66 patients were found (17·7%). Two types of hepatitis were observed: hepatitis B and non-B hepatitis, the latter with an incubation period of between 8 and 60 days. Twelve patients contracted two types of hepatitis, non-B followed by hepatitis B. Only one patient died after contracting hepatitis B. Four of the suspect batches of concentrate were found to be positive for HBsAg by radioimmunoassay.There was evidence that the presence of hepatitis B surface antibody in a patient's serum prior to exposure was associated with immunity to hepatitis B. Evidence was presented suggesting that the non-B hepatitis observed was not due to hepatitis A. The factors affecting the incidence of transfusion hepatitis in haemophiliacs were discussed.

Viral safety of B-domain deleted recombinant factor VIII

2001 ◽  
Vol 38 (2, Suppl 4) ◽  
pp. 32-39 ◽  
Author(s):  
T. S. Charlebois ◽  
B. D. O'Connell ◽  
S. R. Adamson ◽  
H. Brink-Nilsson ◽  
M. Jernberg ◽  
...  
Keyword(s):  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Viral Safety
Sign in / Sign up

Export Citation Format

Share Document